Talecris Biotherapeutics

  Home About Talecris Therapeutic Areas Research & Development Donor to Patient Business Development Investor Relations Media Center  
Investor Relations Home
News
Stock Information
Estimates
Financial Information and SEC Filings
Annual Report and Proxy Statement
Corporate Governance
Presentations
Non-GAAP Reconciliation
Shareholder Information / Stock Transfer
Calendar
Analyst Coverage
Contact

News Release


Printer Friendly Version View printer-friendly version
<< Back
Talecris Biotherapeutics to Report Third Quarter 2009 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 30, 2009-- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) will release its third quarter 2009 financial results on November 9, 2009, after the stock market closes, and will host a conference call at 8:30 AM Eastern Time on November 10, 2009.

Investors and analysts may participate via phone by calling 1-888-713-4199 (domestic) or 1-617-213-4861 (international), passcode number 28819752. To ensure timely access, please dial into the call approximately 10 minutes before it is scheduled to begin. The listen-only webcast will also be available through the Investor Relations section of http://www.talecris.com.

Participants may pre-register for the conference call at https://www.theconferencingservice.com/prereg/key.process?key=PK6K9WQT6. Pre-registrants will be issued a PIN number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

A replay of the conference call will be available beginning approximately two hours after the call concludes and remain accessible until November 17, 2009 by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), passcode number 19852415. The webcast of the conference call will be archived on the Investor Relations section of http://www.talecris.com.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis.

Source: Talecris Biotherapeutics Holdings Corp.

Brunswick Group
Susan Stillings / Greg Faje, 212-333-3810
or
Talecris Investor Relations
John Hanson, 919-316-6139
Chief Financial Officer
investor.relations@talecris.com
or
Talecris Corporate Communications
Becky Levine, 919-316-6590
becky.levine@talecris.com

 

 

Talecris Biotherapeutics
Contact Talecris    Glossary    Site Map
General Conditions of Use    Privacy Statement    California Compliance
© 2009 Talecris Biotherapeutics